These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28873225)

  • 1. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.
    Park H; Chen C; Wang W; Henry L; Cook RL; Nelson DR
    Hepatology; 2018 Feb; 67(2):492-504. PubMed ID: 28873225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.
    Chen YC; Hwang SJ; Li CY; Wu CP; Lin LC
    Medicine (Baltimore); 2015 Aug; 94(32):e1334. PubMed ID: 26266379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.
    Shimada M; Nakamura N; Endo T; Yamabe H; Nakamura M; Murakami R; Narita I; Tomita H
    BMC Nephrol; 2017 Mar; 18(1):109. PubMed ID: 28356063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    Cacoub P; Desbois AC; Isnard-Bagnis C; Rocatello D; Ferri C
    J Hepatol; 2016 Oct; 65(1 Suppl):S82-S94. PubMed ID: 27641990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus infection and glomerular disease.
    Fabrizi F; Donato F; Messa P
    Minerva Urol Nefrol; 2014 Jun; 66(2):139-49. PubMed ID: 24988205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
    Park H; Wang W; Henry L; Nelson DR
    Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.
    Wang W; Lo Re V; Guo Y; Xiao H; Brown J; Park H
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1592-1602. PubMed ID: 32931606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and role of hepatitis-C virus and type II cryoglobulinemia in membranoproliferative glomerulonephritis.
    Prakash S; Dash SC; Kumar A; Dinda AK; Agarwal SK; Acharya SK
    J Assoc Physicians India; 2004 Jun; 52():451-3. PubMed ID: 15645953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
    Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of antiviral therapy for HCV on kidney disease: a systematic review and meta-analysis.
    Fabrizi F; Cerutti R; Dixit V; Messa P
    Nefrologia (Engl Ed); 2020; 40(3):299-310. PubMed ID: 31813592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
    Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
    Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
    BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis.
    De Nicola S; Aghemo A; Campise MR; D'Ambrosio R; Rumi MG; Messa P; Colombo M
    Antivir Ther; 2014; 19(5):527-31. PubMed ID: 24009104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature.
    Humphries K; Darling JM; Barritt AS
    Dig Dis Sci; 2014 Aug; 59(8):2007-12. PubMed ID: 24633573
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD.
    Zhang H; Xu H; Wu R; Yu G; Sun H; Lv J; Wang X; Chi X; Gao X; Kong F; Zhang M; Hang L; Jiang J; Pan Y; Niu J
    Sci Rep; 2019 Feb; 9(1):1910. PubMed ID: 30760762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection.
    Park H; Adeyemi A; Henry L; Stepanova M; Younossi Z
    J Viral Hepat; 2015 Nov; 22(11):897-905. PubMed ID: 25904153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.
    Alric L; Plaisier E; Thébault S; Péron JM; Rostaing L; Pourrat J; Ronco P; Piette JC; Cacoub P
    Am J Kidney Dis; 2004 Apr; 43(4):617-23. PubMed ID: 15042538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evidence-based epidemiology of HCV-associated kidney disease.
    Fabrizi F; Dixit V; Martin P; Messa P
    Int J Artif Organs; 2012 Sep; 35(9):621-8. PubMed ID: 22886564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons.
    Mocroft A; Ryom L; Oprea C; Li Q; Rauch A; Boesecke C; Uzdaviniene V; Sedlacek D; Llibre JM; Lacombe K; Nielsen LN; Florence E; Aho I; Chkhartishvili N; Szlavik J; Dragovic G; Leen C; Sambatakou H; Staub T; Laguno M; Elinav H; Tomažič J; Peters L;
    AIDS; 2020 Aug; 34(10):1485-1495. PubMed ID: 32675562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection.
    Chen YC; Li CY; Tsai SJ; Chen YC
    World J Gastroenterol; 2018 Feb; 24(8):917-928. PubMed ID: 29491685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.